Anti-tumor effects in combination with PARP inhibitor and DNMT inhibitor in ovarian cancer

被引：0
|
作者：
Lee, Jeong-Won [1 ]
Jeong, Soo Young [1 ]
Ryu, Ji Yoon [1 ]
Lee, Yoo-Young [1 ]
Esun, Paik [1 ]
机构：
[1] Samsung Med Ctr, Seoul, South Korea
来源：
CANCER RESEARCH | 2019年 / 79卷 / 13期
关键词：
D O I：
10.1158/1538-7445.AM2019-377
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
377
引用
收藏
页数：2
相关论文
共 50 条
  • [41] PARP Inhibitor Resistance and Acquired Vulnerability in Ovarian Cancer
    D'Andrea, Alan
    ONCOLOGIST, 2017, 22 : S1 - S1
  • [42] PARP Inhibitor Treatment in Ovarian and Breast Cancer Foreword
    Kummar, Shivaani
    CURRENT PROBLEMS IN CANCER, 2011, 35 (01) : 6 - 6
  • [43] Olaparib: a promising PARP inhibitor in ovarian cancer therapy
    Chen, Ying
    Zhang, Lei
    Hao, Quan
    ARCHIVES OF GYNECOLOGY AND OBSTETRICS, 2013, 288 (02) : 367 - 374
  • [44] Olaparib, PARP1 inhibitor in ovarian cancer
    Marchetti, Claudia
    Imperiale, Ludovica
    Gasparri, Maria Luisa
    Palaia, Innocenza
    Pignata, Sandro
    Boni, Terenzio
    Bellati, Filippo
    Panici, Pierluigi Benedetti
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2012, 21 (10) : 1575 - 1584
  • [45] Diverse mechanisms of PARP inhibitor resistance in ovarian cancer
    Wakefield, Matthew John
    Nesic, Ksenija
    Kondrashova, Olga
    Scott, Clare L.
    BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, 2019, 1872 (02):
  • [46] Olaparib: a promising PARP inhibitor in ovarian cancer therapy
    Ying Chen
    Lei Zhang
    Quan Hao
    Archives of Gynecology and Obstetrics, 2013, 288 : 367 - 374
  • [47] Anti-tumor effects of a novel MEK inhibitor in combination with cytotoxic chemotherapy in human melanoma cell lines
    Denton, Cathrine L.
    Gustafson, Daniel L.
    CANCER RESEARCH, 2006, 66 (08)
  • [48] GM101 in Combination with Histone Deacetylase Inhibitor Enhances Anti-Tumor Effects in Desmoplastic Microenvironment
    Chang, Han-Gyu
    Choi, Yong-Hyeon
    Hong, JinWoo
    Choi, Joung-Woo
    Yoon, A-Rum
    Yun, Chae-Ok
    CELLS, 2021, 10 (11)
  • [49] PARP inhibitor combination therapy
    Drean, Amy
    Lord, Christopher J.
    Ashworth, Alan
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2016, 108 : 73 - 85
  • [50] KLF5 Promotes Tumor Progression and Parp Inhibitor Resistance in Ovarian Cancer
    Wu, Yong
    Chen, Siyu
    Shao, Yang
    Su, Ying
    Li, Qin
    Wu, Jiangchun
    Zhu, Jun
    Wen, Hao
    Huang, Yan
    Zheng, Zhong
    Chen, Xiaojun
    Ju, Xingzhu
    Huang, Shenglin
    Wu, Xiaohua
    Hu, Zhixiang
    ADVANCED SCIENCE, 2023, 10 (31)
12345